Physician profile
Paul Paul Lenkowski
NPI 1497964886
$281,522.83
in general payments reported to CMS, 2019-2025
24 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,300 · 2020: $2,641 · 2021: $49K · 2022: $60K · 2023: $31K · 2024: $55K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $106K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Travel and Lodging: $8,483 · Food and Beverage: $8,476 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $106,462.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,075.60 |
| Travel and Lodging | $8,483.33 |
| Food and Beverage | $8,475.75 |
| Education | $352.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $208,085.05 | 2019-2025 | Latera, Xpress Loprofile, Scopis Ent |
| Optinose US, INC. | $40,006.47 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $22,434.56 | 2019-2025 | Dupixent |
| Genzyme Corporation | $8,747.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $976.99 | 2022-2025 | Nucala |
| Kaleo, INC. | $209.12 | 2020-2023 | Auvi-Q |
| Genentech USA, INC. | $170.88 | 2019-2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $163.27 | 2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $140.55 | 2022-2025 | |
| Intersect Ent, INC. | $132.00 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.76 | 2022 | |
| Medtronic, INC. | $53.80 | 2024 | Propel |
| Vertex Pharmaceuticals Incorporated | $48.54 | 2025 | |
| Arbor Pharmaceuticals, INC. | $46.02 | 2019 | |
| Inspire Medical Systems, INC. | $44.30 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.56 | 2023 | |
| Greer Laboratories, INC. | $29.18 | 2025 | Oralair |
| Amgen INC. | $28.47 | 2025 | Tezspire |
| Phadia US INC. | $22.10 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $20.34 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.97 | 2022 | |
| Horizon Therapeutics Plc | $15.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.57 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lenkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.